Cart
sales@molnova.com
Rizatriptan benzoate
CAS No. 145202-66-0
Rizatriptan benzoate( MK-462 )
Catalog No. M11948 CAS No. 145202-66-0
Rizatriptan Benzoate(Maxalt) is a 5-HT1 agonist triptan drug for the treatment of migraine headaches.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 35 | In Stock |
|
| 25MG | 65 | In Stock |
|
| 50MG | 115 | In Stock |
|
| 100MG | 174 | In Stock |
|
| 200MG | 258 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRizatriptan benzoate
-
NoteResearch use only, not for human use.
-
Brief DescriptionRizatriptan Benzoate(Maxalt) is a 5-HT1 agonist triptan drug for the treatment of migraine headaches.
-
DescriptionRizatriptan Benzoate(Maxalt) is a 5-HT1 agonist triptan drug for the treatment of migraine headaches.
-
In Vitro——
-
In Vivo——
-
SynonymsMK-462
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptor5-HT
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number145202-66-0
-
Formula Weight391.47
-
Molecular FormulaC22H25N5O2
-
Purity>98% (HPLC)
-
SolubilityWater: 46 mg/mL (117.5 mM); DMSO: 20 mg/mL (51.08 mM)
-
SMILESCN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3.C1=CC=C(C=C1)C(=O)O
-
Chemical Name2-(5-((1H-1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)-N,N-dimethylethan-1-amine benzoate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wellington K, Plosker GL. Drugs. 2002;62(10):1539-74.
molnova catalog
related products
-
Azaphen
Azaphen is the reuptake of serotonin inhibitor.with antidepressant action and has sedative effects suggesting antihistamine activity.?
-
SB 737050A
SB 737050A is a potent, selective 5-HT6 receptor antagonist to prevent relapse intio addiction.
-
SEP-363856 hydrochlo...
SEP-363856 hydrochloride is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor.
